Ozler Talar, Cosar Rusen, Sut Necdet, Nurlu Dilek, Parlar Şule, Ateş Sinan, Dertli Mert Hacı, Kavuzlu Yusuf, Kavukcu Sekip, Chousein Mert, Yıldız Gokay, Tunçbilek Nermin, Hacıoglu Muhammet Bekir, Tastekin Ebru, Topaloğlu Sernaz
Department of Radiation Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Department of Biostatistics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Breast Cancer Res Treat. 2025 Apr;210(3):673-686. doi: 10.1007/s10549-024-07606-1. Epub 2025 Jan 9.
The characteristics of patients with bilateral and unilateral breast cancer at the time of diagnosis or during follow-up have been compared, focusing on the differences in disease-free survival and overall survival between these groups.
A total of 1,947 patients diagnosed with invasive carcinoma were included in the study. 1876 (96.4%) of our patients had unilateral and 71 (3.6%) had bilateral breast cancer. Among the bilateral breast cancer patients n = 47 were metachronous, while n = 24 were synchronous.
SBBC, which had the lowest OS duration, showed a statistically significant difference compared to MBCC, similar to that observed in unilateral breast cancer (p = 0.027).
The fact that SBBC has the lowest survival rate despite more aggressive treatments should be considered a poor prognostic factor for survival on its own.
比较双侧和单侧乳腺癌患者在诊断时或随访期间的特征，重点关注这些组之间无病生存期和总生存期的差异。
本研究共纳入1947例诊断为浸润性癌的患者。我们的患者中有1876例（96.4%）为单侧乳腺癌，71例（3.6%）为双侧乳腺癌。在双侧乳腺癌患者中，47例为异时性，24例为同时性。
总生存期最短的双侧乳腺癌与多原发性双侧乳腺癌相比有统计学显著差异，与单侧乳腺癌中观察到的情况相似（p = 0.027）。
尽管采用了更积极的治疗方法，但双侧乳腺癌的生存率最低，这一事实本身就应被视为生存的不良预后因素。
